Treating to goal: New strategies for initiating and optimizing lipid-lowering therapy in patients with atherosclerosis

Vascular Medicine

Volumn 7, Issue 3, 2002, Pages 187-194

  Fonarow, Gregg C ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Atherosclerosis; Low density lipoprotein; NCEP ATP III guidelines; Statins; Undertreatment

Indexed keywords

ACETYLSALICYLIC ACID; ANTILIPEMIC AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHOLESTEROL; CHOLESTEROL ACYLTRANSFERASE INHIBITOR; CHOLESTEROL ESTER TRANSFER PROTEIN INHIBITOR; COLESEVELAM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPTIFIBATIDE; EZETIMIBE; FIBRIC ACID DERIVATIVE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ITAVARSTATIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; RESIN; ROSUVASTATIN; SIMVASTATIN; STREPTOKINASE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FLUSHING; HEALTH SURVEY; HEART PROTECTION; HOSPITAL ADMISSION; HUMAN; HYPERLIPIDEMIA; LIPID ANALYSIS; LIPOPROTEIN BLOOD LEVEL; LONG TERM CARE; MEDICAL RECORD; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK FACTOR; RISK MANAGEMENT; SHORT COURSE THERAPY; SIDE EFFECT;

ANTILIPEMIC AGENTS; CHOLESTEROL, LDL; CORONARY ARTERIOSCLEROSIS; EUROPE; HUMANS; PATIENT COMPLIANCE; PHYSICIAN'S ROLE; RISK REDUCTION BEHAVIOR; UNITED STATES;

EID: 0036961455     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x02v427ra     Document Type: Review

References (53)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-97.
2. Pearson TA, Laurora I, Chu H, Kafonek S. The Lipid Treatment Assessment Project (L-TAP). A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000; 160: 459-67.
3. EUROASPIRE II Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries: Principal results from EUROASPIRE II. Eur Heart J 2001; 22: 554-72.
4. National Cholesterol Education Program. Second report of the Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). Circulation 1994; 89: 1329-445.
5. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998; 339: 229-34.
6. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannel WB. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA 1986; 256: 2835-38.
7. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341: 498-511
8. Maron DJ, Fazio S, Linton MF. Current perspectives on statins. Circulation 2000; 101: 207-13.
9. McKenney JM. Lipid management: Tools for getting to the goal. Am J Manag Care 2001; 7 (9 suppl): S299-S306.
10. Downs JR, Clearfield M, Weiss S et al, for the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS. JAMA 1998; 279: 1615-22.
11. Shepherd J, Cobbe SM, Ford I et al, for the West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-307.
12. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344: 1383-89.
13. Sacks FM, Pfeffer MA, Moye LA et al, for the Cholesterol And Recurrent Events Trial Investigators. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335: 1001-1009.
14. The Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998; 339: 1349-57.
15. Heart Protector Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
16. American Heart Association. 2002 Heart and Stroke Statistical Update. Dallas, TX: American Heart Association, 2001.
17. Murray CL, Lopez AD (eds). The Global Burden of Disease. A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries and Risk Factors in 1990 and Projected to 2020. GBD Series, Vol. I. Cambridge, MA: Harvard School of Public Health on behalf of the World Health Organization and the World Bank, 1996.
18. Fonarow GC, French WJ, Parsons LS, Sun H, Malmgren JA. Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: Data from the National Registry of Myocardial Infarction 3. Circulation 2001; 103: 38-44.
19. Aronow HD, Topol EJ, Roe MT et al. Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: An observational study. Lancet 2001; 357: 1063-68.
20. Pearson TA, McBride PE, Miller NH, et al. 27th Bethesda Conference: Matching the intensity of risk factor management with the hazard for coronary disease events. Task Force 8. Organization of preventive cardiology service. J Am Coll Cardiol 1996; 27: 1039-47.
21. Fonarow GC, Ballantyne CM. In-hospital initiation of lipid-lowering therapy for patients with coronary heart disease: The time is now. Circulation 2001; 103: 2768-70.
22. Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. The Expert Panel. Arch Intern Med 1988; 148: 36-69.
23. McCall M, Elmfeldt D, Vedin A, Wilhelmsson C, Wedel H, Wilhelmsen L. Influence of a myocardial infarction on blood pressure and serum cholesterol. Acta Med Scand 1979; 206: 477-81.
24. Rosenson RS. Myocardial injury: The acute phase response and lipoprotein metabolism. J Am Coll Cardiol 1993; 22: 933-40.
25. Fonarow GC, Gawlinski A, Moughrabi S, Tillisch JH. Improved treatment of coronary heart disease by implementation of a Cardiac Hospitalisation Atherosclerosis Management Program (CHAMP). Am J Cardiol 2001; 87: 819-22.
26. Foody JM, Nissen SE. Effectiveness of statins in acute coronary syndromes. Am J Cardiol 2001; 88 (suppl): 31F-35F.
27. Muhlestein JB, Horne BD, Bair TL et al. Usefulness of in-hospital prescription of statin agents after angiographic diagnosis of coronary artery disease in improving continued compliance and reduced mortality. Am J Cardiol 2001; 87: 257-61.
28. Pearson RR, Horne BD, Maycock CA et al. An institutional discharge medication program reduces future cardiovascular readmissions and mortality: An analysis of 43,841 patients with coronary artery disease. J Am Coll Cardiol 2002; 39: 452A.
29. McCarthy M. US heart-guidelines program makes a promising start. Lancet 2001; 358: 1618.
30. Schwartz GG, Olsson AG, Ezekowitz MD et al, for the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL Study: A randomised controlled trial. JAMA 2001; 285: 1711-18.
31. Heeschen C, Hamm CW, Laufs U et al on behalf of the Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM) Investigators. Withdrawal of statins increases event rates in patients with acute coronary syndromes. Circulation 2002; 105: 1446-52.
32. Rosenson RS, Tangney CC. Antiatherothrombotic properties of statins: Implications for cardiovascular event reduction. JAMA 1998; 279: 1643-50.
33. Kwak B, Mulhaupt F, Myit S et al. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6: 1399-402.
34. Blazing MA, De Lemos JA, Dyke CK, Califf RM, Bilheimer D, Braunwald E. The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy. Am Heart J 2001; 142: 211-17.
35. Gotto AM Jr. Ongoing clinical trials of statins. Am J Cardiol 2001; 88 (suppl): 36F-40F.
36. Smith SCJ, Blair SN, Bono RO et al. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. Circulation 2001; 104: 1577-79.
37. Braunwald E, Antman EM, Beasley JW et al. ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction: A report of the American College of Cardiology/American Heart Association Task Force of on Practice Guidelines. 2002.
38. Hunninghake DB. Postdischarge lipid management of coronary artery disease patients according to the new national cholesterol education program guidelines. Am J Cardiol 2001; 88 (suppl): 37K-41K.
39. Debusk RF, Miller NH, Superko HR et al. A case-management system for coronary risk factor modification after acute myocardial infarction. Ann Intern Med 1994; 120: 721-29.
40. Kinn JW, Brown AS. Cardiovascular risk management in clinical practice: The midwest heart specialists experience. Am J Cardiol 2002; 89 (suppl): 23C-29C.
41. Birtcher KK, Bowden C, Ballantyne CM et al. Strategies for implementing lipid-lowering therapy: Pharmacy-based approach. Am J Cardiol 2000; 85 (suppl): 30A-35A.
42. Blair TP, Bryant FJ, Bocuzzi S. Treatment of hypercholesterolemia by a clinical nurse using a stepped-care protocol in a nonvolunteer population. Arch Intern Med 1988; 148: 1046-48.
43. Brown AS, Bakker-Arkema RG, Yellen L et al. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-density-lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Coll Cardiol 1998; 32: 665-72.
44. Davidson M, Ma P, Stein EA et al. Comparison of effects of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol with rosuvastatin vs. atorvastatin in patients with type IIa or IIb hypercholesterolemia. Am J Cardiol 2002; 89: 268-75.
45. Paoletti R, Fahmy M, Mahla G, Mizan J, Southworth H. Rosuvastatin demonstrates greater reduction of low-density lipoprotein in hypercholesterolaemic patients: A randomized double-blind study. J Cardiovasc Risk 2001; 8: 383-90.
46. Aldridge MA, Ito MK. Colesevelam hydrochloride: A novel bile acid-binding resin. Ann Pharmacother 2001; 35: 898-907.
47. Knapp HH, Schrott H, Ma P et al. Efficacy and safety of combination simvastatin and colesevelam in patients with primary hypercholesterolemia. Am J Med 2001; 110: 352-60.
48. Kashyap ML, McGovern ME, Berra K et al. Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. Am J Cardiol 2002; 89: 672-78.
49. De Grooth GJ, Kuivenhoven JA, Stalenhoef AF et al. Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans. A randomized phase II dose-response study. Circulation 2002; 105: 2159-65.
50. Insull W Jr, Koren M, Davignon J et al. Efficacy and short-term safety of a new ACAT inhibitor, avasimibe, on lipids, lipoproteins, and apolipoproteins, in patients with combined hyperlipidemia. Atherosclerosis 2001; 157: 137-44.
51. Kosoglou T, Meyer I, Musiol B et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin. Atherosclerosis 2000; 151: 135 [abstract].
52. Kosoglou T, Seiberling M, Statkevich P et al. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and atorvastatin. J Am Coll Cardiol 2001; 37 (suppl A): 229A.
53. Fonarow GC. Statin therapy after acute myocardial infarction: Are we adequately treating high risk patients? Curr Atheroscler Rep 2002, 4: 99-106.